In the fast-evolving landscape of biotechnology, speed and precision are critical. Athos Therapeutics, Inc., a pioneering biotech company, has significantly progressed in developing AI-driven precision therapeutics for autoimmune diseases and cancer. Leveraging Vultr's high-performanceGPUs, Athos can accelerate the discovery of next-generation treatments, driving medical innovation to new heights.
Transforming autoimmune and cancer treatment with AI
Athos is at the forefront of biotech innovation, utilizing a systems biology approach to analyze molecular interactions and disease pathways. By integrating clinical and molecular datasets into disease interactomes, Athos identifies novel drug targets. Their proprietary drug development platform has analyzed samples from over 25,000 patients, uncovering new therapeutic targets across various autoimmune diseases and cancers.
"Our platform identifies novel drug targets by integrating clinical and molecular datasets into disease interactomes and matches them to our small-molecule computational chemistry platform," explained Dr. Dimitra Chalkia, VP of Computational Biology at Athos. "We've discovered groundbreaking targets like our lead compound ATH-063 for Inflammatory Bowel Disease (IBD)."
The need for scalable, cost-effective cloud infrastructure
As a clinical-stage biotechnology company, Athos required a robust cloud infrastructure that could scale with growing data needs. Previously reliant on traditional public cloud solutions, Athos faced challenges with high costs and limited engineering support. Their search for a more agile and efficient platform led them to Vultr.
"Our datasets grow every year, making it crucial to have scalable and secure GPU infrastructure. Vultr, powered by NVIDIA and Dell technologies, allows us to train large datasets for precision medicine efficiently," said June Guo, VP of AI & Machine Learning at Athos.
Harnessing the power of NVIDIA HGX H100 on Vultr Cloud GPU
Athos's switch to Vultr's NVIDIA HGX H100 GPUs has been a game-changer. The advanced capabilities of the NVIDIA H100 Tensor Core GPU, with its transformer engine, enable Athos to train large models with mixed precision, significantly speeding up AI model iterations.
“Besides reliable access to NVIDIA HGX H100s, Vultr’s excellent engineering support minimizes downtime, ensuring our computational teams stay productive,” added Guo.
With Vultr, Athos benefits from:
- Scalable GPU solutions that support rapid hardware upgrades, reducing long-term costs.
- User-friendly interfaces for seamless interaction with computational resources.
- Cost efficiency by eliminating the need to maintain their data centers.
- Comprehensive engineering support for hardware and software issues.
- Data security is crucial for protecting sensitive patient data, proprietary AI algorithms, and intellectual property.
Driving innovation in drug discovery and beyond
The partnership with Vultr and Dell has enabled Athos to optimize its AI workflows, significantly accelerating its drug discovery process. This infrastructure supports Athos's mission to bring novel precision therapeutics to market, particularly for conditions that have long been underserved.
"Athos is committed to providing novel treatments for patients with autoimmune diseases and cancer. The combination of Vultr Cloud GPU, powered by NVIDIA, and Dell infrastructure helps us achieve our aims," said Dimitrios Iliopoulos, PhD MBA, President and CEO of Athos.
As Athos continues to advance its precision medicine initiatives, the company exemplifies how AI and cloud technologies can transform biotech. Their work is a testament to how innovative cloud solutions like Vultr's can empower companies to scale operations, reduce costs, and ultimately bring life-saving treatments to market faster.
Looking to power your healthcare innovations with scalable cloud infrastructure? Explore how Vultr supports healthcare and life sciences organizations here. For a deeper dive into the latest industry trends and insights, download our comprehensive healthcare report here.